Sweden · Delayed Price · Currency is SEK Inhalation Sciences Sweden AB Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 revenue exceeded SEK 4 million, surpassing all of 2025, with SEK 2.5 million in new orders and a robust SEK 20 million pipeline. The M&A process is ongoing, aiming for completion before summer 2026, while regulatory changes in the U.S. present challenges.
-
Q4 sales exceeded SEK 5 million, with a strong order pipeline driven by FDA collaboration and marketing efforts. An ongoing M&A process aims to unlock further value, while warrants and a guarantor secure liquidity during negotiations.
-
Sales and revenue doubled year-over-year in H1 2026, with a strong SEK 30 million pipeline and new U.S. market activities. A SEK 4 million loan provides stability for ongoing M&A evaluation and continued growth.
Fiscal Year 2025
-
Q3 and year-to-date revenues declined year-over-year, but operating expenses were reduced by SEK 3 million. Strategic initiatives include a new communication campaign, a major conference presence, and an M&A process with PharmaVentures, targeting completion by H1 2026.
-
FDA-backed study results and a SEK 10 million rights issue highlight a strong Q2, with reduced R&D costs and a robust sales pipeline. Regulatory trends and a new awareness campaign position the company for commercial growth.